Bayer buys Algeta

Share this article:

Bayer is ponying up $2.9 billion to buy now-former oncology partner Algeta, reports PMLive. The deal means Bayer will own the prostate cancer therapy Xofigo outright.

The company previously estimated the alpha-particle-emitting therapeutic agent would hit $1.3 billion in annual sales.

The FDA approved the treatment in May.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.